| HOME >> MEDICINE >> TECHNOLOGY |
(104,247)-(104,247)- Income tax adjustments
(1,989)-4,171- Adjusted net income
$
93,946$
55,418$
290,394$
4,884 GAAP income from continuing operations per diluted share
$
2.71$
.79$
4.34$
2.67 Adjusted net income per diluted share
$
.53$
.17$
4.82$
3.52 Shares used in computing GAAP income from continuing operations and adjusted net income per diluted share amounts
61,23447,45160,19546,798 JAZZ PHARMACEUTICALS PLC RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (In thousands, except per share amounts) (Unaudited) Three Months EndedDecember 31, 2012December 31, 2011GAAPAdjustmentNon-GAAPGAAPAdjustmentNon-GAAPTotal revenues
$
83,703$
-$
83,703$
83,536$
(284)
(f)
$
83,252Cost of product sales
25,763(2,614)
(a)
23,1493,862(194)
(c)
3,668Selling, general and administrative
61,377(7,242)
(b)
54,13536,384(13,877)
(g)
22,507Research and development
7,277(922)
(c)
6,3553,764(2,146)
(c)
1,618Intangible asset amortization
21,907(21,907)-1,862(1,862)-Interest expense, net
7,670(1,291)
(d)
6,37941-41Foreign currency loss
2,263-2,263---Loss on extinguishment of debt
---150(150)-Income tax provision (benefit)
(108,760)106,236
(e)
(2,524)---Income from continuing operations
166,206(72,260)93,94637,47317,94555,418Income from continuing operations per diluted share
$
2.71$
.53$
.79$
.17(a)
'/>"/>SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May